According to the Zhitong Finance App, Shanghai Pharmaceutical (02607.HK) announced its 2026 interim results, with operating income of about 147.47 billion yuan, up 4.15% year on year; net profit attributable to shareholders of listed companies was about 3.54 billion yuan, a decrease of 21.4% year on year; basic earnings per share were 0.95 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.